DCF Advisers’s Matinas BioPharma MTNB Stock Holding History

DCF Advisers’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,090	Closed	-$156K	–	81
2021 Q4	$156K	Hold	3,090	–	–	0.06%	70
2021 Q3	$201K	Sell	3,090 -4,629	-60%	-$200K	0.09%	78
2021 Q2	$299K	Sell	7,719 -281	-4%	-$12.1K	0.11%	83
2021 Q1	$420K	Buy	8,000 +1,894	+31%	+$127K	0.18%	82
2020 Q4	$415K	Sell	6,106 -4,930	-45%	-$228K	0.17%	74
2020 Q3	$423K	Sell	11,036 -240	-2%	-$9.54K	0.22%	65
2020 Q2	$436K	Sell	11,276 -1,124	-9%	-$43.1K	0.24%	59
2020 Q1	$372K	Buy	12,400 +6,920	+126%	+$418K	0.24%	52
2019 Q4	$622K	Buy	+5,480	New	+$318K	0.39%	48

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AWA

Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

CCM

Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCA

STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return

DCF Advisers's MTNB Position: Q1 2022 in Review

DCF Advisers sold out of Matinas BioPharma (MTNB) in Q1 2022, closing a stake of 3,090 shares — an estimated $156K sold.

DCF Advisers first reported a position in MTNB in Q4 2019 and held it in 9 quarters. The position peaked at $622K in Q4 2019. 56 funds tracked by Wall St. Rank hold MTNB as of Q1 2022.

DCF Advisers reported no remaining Matinas BioPharma position as of Q1 2022 after selling out during the quarter.
DCF Advisers sold 3,090 Matinas BioPharma shares in Q1 2022, an estimated $156K.
DCF Advisers first reported a position in Matinas BioPharma in Q4 2019 and held it in 9 quarters.
DCF Advisers's Matinas BioPharma position peaked at $622K in Q4 2019.
56 funds tracked by Wall St. Rank held Matinas BioPharma as of Q1 2022.

Based on DCF Advisers's 13F filing for Q1 2022, filed 13 May 2022.